Gut microbiota may be involved in Alzheimer’s disease pathology by dysregulating pyrimidine metabolism in APP/PS1 mice

Min Feng, Tianshu Hou, Mingze Zhou, Qiuyu Cen, Ting Yi, Jinfeng Bai, Yun Zeng, Qi Liu, Cheng-Shun Zhang, Ying‐Jun ZhangFrontiers in Aging Neuroscience 2022 · DOI

Abstract

Gut microbiota may be involved in the pathological processes associated with cognitive impairment in AD by dysregulating pyrimidine metabolism. B. firmus, Rikenella, Clostridium sp. Culture-27, and deoxyuridine may be important biological markers for AD. Our findings provide new insights into the host-microbe crosstalk in AD pathology and contribute to the discovery of diagnostic markers and therapeutic targets for AD.

Introduction

While the "gut-brain axis" has become a focal point in neurodegenerative research, the specific mechanisms by which gut bacteria influence Alzheimer’s Disease (AD) pathology remain largely uncharacterized. Current research acknowledges that AD patients and animal models exhibit gut dysbiosis, but the functional metabolic pathways being hijacked—and the specific metabolites they produce—require deeper investigation. This study aims to map the functional crosstalk between the gut microbiome and the host's metabolic profile to identify the specific pathways that correlate with cognitive decline.

Methods and Materials

The researchers utilized a multi-omic approach on seven-month-old APP/PS1 double-transgenic mice, a standard model for AD, compared to wild-type controls. The workflow included:

  • Behavioral Testing: The Morris Water Maze (MWM) was used to quantify spatial learning and memory deficits.
  • Microbiome Profiling: 16S rRNA gene sequencing (V4 region) to identify the composition and diversity of gut bacteria.
  • Widely Targeted Metabolomics: UPLC-MS/MS (Ultra-high performance liquid chromatography-tandem mass spectrometry) was employed to analyze fecal metabolic profiles.
  • Integrated Analysis: Spearman’s correlation linked specific differential bacteria to metabolites, followed by KEGG pathway enrichment to identify affected biological systems.

Results

Cognitive Impairment and Microbial Shifts

Behavioral assessments confirmed significant cognitive deficits in the APP/PS1 mice. The AD group exhibited significantly longer escape latencies in the MWM ($P = 0.004$), indicating impaired spatial learning and memory acquisition.

Figure 4: Escape latency (sec) in the Morris Water Maze, showing increased time to find the platform in the AD model.

Microbial profiling revealed a significant reduction in $\beta$-diversity ($P < 0.01$) in AD mice, suggesting a less stable microbial community. The study identified Bacillus firmus and Rikenella as the top bacterial taxa associated with significant changes in fecal metabolites. Furthermore, AD mice showed a significantly higher ratio of Firmicutes to Bacteroidota, a metric often considered a hallmark of cognitive aging.

The Pyrimidine Connection

Metabolomic analysis identified 40 differential fecal metabolites, with 31 being significantly downregulated in the AD group. The most significant finding was the perturbation of pyrimidine metabolism ($P = 0.044$). Pyrimidines are essential for DNA/RNA synthesis and mitochondrial function; the study found that three key metabolites in this pathway—deoxycytidine, 2’-deoxyuridine, and thymidine—were significantly depleted in AD mice.

Figure 5: Additional spatial memory metrics, including percentage of time and distance spent in the target quadrant during probe trials.

Discussion and Limitations

These findings suggest that gut microbiota dysregulation may drive AD pathology by impairing pyrimidine metabolism. The correlation between specific taxa, such as Clostridium sp. Culture-27, and metabolites like deoxycytidine points toward potential new diagnostic markers and therapeutic targets.

However, the authors acknowledge several limitations. This was a prospective, observational study; while the correlations are strong, they do not definitively prove that gut dysbiosis causes the pyrimidine disorder. Additionally, while the APP/PS1 model is a standard in AD research, human clinical trials are necessary to validate these biomarkers. Future work should include metabolomic analysis of serum and cerebrospinal fluid to determine if these pyrimidine deficits are systemic or localized to the gut.

Summary updated

Abstract

Gut microbiota may be involved in the pathological processes associated with cognitive impairment in AD by dysregulating pyrimidine metabolism. <i>B. firmus</i>, <i>Rikenella</i>, <i>Clostridium</i> sp. Culture-27, and deoxyuridine may be important biological markers for AD. Our findings provide new insights into the host-microbe crosstalk in AD pathology and contribute to the discovery of diagnostic markers and therapeutic targets for AD.
BibTeX
@inproceedings{feng2022gut,
  author = {Min Feng and Tianshu Hou and Mingze Zhou and Qiuyu Cen and Ting Yi and Jinfeng Bai and Yun Zeng and Qi Liu and Cheng-Shun Zhang and Ying‐Jun Zhang},
  title = {{Gut microbiota may be involved in Alzheimer’s disease pathology by dysregulating pyrimidine metabolism in APP/PS1 mice}},
  booktitle = {Frontiers in Aging Neuroscience},
  year = {2022},
  doi = {10.3389/fnagi.2022.967747},
}
Figure